Literature DB >> 20077761

Gender differences in the genetic risk for alcohol dependence--the results of a pharmacogenetic study in Korean alcoholics.

Sung-Gon Kim1.   

Abstract

The genotype frequencies of the ADH2 and ALDH2 gene polymorphisms as well as the A118G polymorphism of the mu opioid receptor gene (OPRM1) in Korean men and women with alcohol dependence (AD) were compared with those of normal healthy (NH) Korean men and women at a low risk for alcoholism. 1) The frequencies of the ADH2*1/1 and ALDH2*1/1 genotypes were significantly higher in the AD men than in the NH men. However, the frequencies of the ADH2*1/1 and ALDH2*1/2 or 2/2 genotypes were significantly higher in the AD women than in the NH women. And 92% of AD men have the ALDH2*1/1 genotype, while 61% of AD women have the ADH2*1/1 genotype. 2) A gender comparison of the AD and NH groups revealed a significantly higher frequency of the A/G or G/G (hereinafter G carrier) genotypes of the OPRM1 A118G polymorphism in AD women. but not in AD men. These results suggest that, while the risk of alcoholism in Korean men is predominantly affected by the presence of the ALDH2 1/1 genotype, the risk of alcoholism in Korean women is primarily associated with the ADH2 1/1 genotype and G carrier genotype of the OPRM1 A118G polymorphism. It appears that these gender differences make it easier for alcoholic women to become intoxicated, thus making them more vulnerable to developing alcoholism. Our finding that naltrexone treatment was more effective in terms of time to first relapse in Korean AD men with the G carrier genotype than in those with the A/A genotype suggests that there is the possibility that naltrexone is more effective in the treatment of Korean AD women AD with the G carrier genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20077761

Source DB:  PubMed          Journal:  Nihon Arukoru Yakubutsu Igakkai Zasshi        ISSN: 1341-8963


  8 in total

1.  No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample.

Authors:  Momchil A Nikolov; Olga Beltcheva; Antoaneta Galabova; Anna Ljubenova; Elena Jankova; Galin Gergov; Atanas A Russev; Michael T Lynskey; Elliot C Nelson; Eleonora Nesheva; Dorita Krasteva; Philip Lazarov; Vanio I Mitev; Ivo M Kremensky; Radka P Kaneva; Alexandre A Todorov
Journal:  Drug Alcohol Depend       Date:  2011-01-31       Impact factor: 4.492

Review 2.  The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.

Authors:  Lara A Ray; Christina S Barr; Julie A Blendy; David Oslin; David Goldman; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2011-09-06       Impact factor: 3.455

Review 3.  Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

Authors:  Anita Cservenka; Megan M Yardley; Lara A Ray
Journal:  Am J Addict       Date:  2016-11-04

4.  Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study.

Authors:  Eric A Woodcock; Leslie H Lundahl; Margit Burmeister; Mark K Greenwald
Journal:  Am J Addict       Date:  2015-04-24

5.  Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.

Authors:  Aaron C Lim; Dara G Ghahremani; Erica N Grodin; ReJoyce Green; Spencer Bujarski; Emily E Hartwell; Kelly E Courtney; Kent Hutchison; Karen Miotto; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2019-05-09       Impact factor: 4.852

6.  μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer.

Authors:  Anna Cieślińska; Edyta Sienkiewicz-Szłapka; Elżbieta Kostyra; Ewa Fiedorowicz; Jadwiga Snarska; Konrad Wroński; Michał Tenderenda; Beata Jarmołowska; Michał Matysiewicz
Journal:  Tumour Biol       Date:  2015-01-25

7.  Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.

Authors:  João M Castaldelli-Maia; André Malbergier; Adriana B P de Oliveira; Ricardo A Amaral; André B Negrão; Priscila D Gonçalves; Antonio Ventriglio; Domenico de Berardis; Juliana de Antonio; Isabela Firigato; Gilka J F Gattás; Fernanda de Toledo Gonçalves
Journal:  Biomolecules       Date:  2021-10-10

8.  Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.

Authors:  Lara A Ray; ReJoyce Green; Daniel J O Roche; Spencer Bujarski; Emily E Hartwell; Aaron C Lim; Taylor Rohrbaugh; Dara Ghahremani; Kent Hutchison; Karen Miotto
Journal:  Alcohol Clin Exp Res       Date:  2018-02-01       Impact factor: 3.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.